On October 22, 2025, Tonix Pharmaceuticals reported that the first patient was dosed in their FOCUS study at Massachusetts General Hospital for treating arginine-vasopressin deficiency with investigational drug candidates. The study will evaluate two dosages of intranasal oxytocin on mental health outcomes.